BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by ($0.39), Zacks reports.
BriaCell Therapeutics Trading Down 4.7 %
NASDAQ BCTX opened at $3.88 on Wednesday. The firm’s fifty day simple moving average is $4.67 and its two-hundred day simple moving average is $9.00. BriaCell Therapeutics has a 12-month low of $3.00 and a 12-month high of $45.45. The firm has a market capitalization of $14.39 million, a P/E ratio of -0.29 and a beta of 1.71.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lifted their price target on shares of BriaCell Therapeutics from $15.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, February 3rd.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- EV Stocks and How to Profit from Them
- Delta’s Stock Takes a Hit—Can Lower Oil Prices Fuel a Comeback?
- What is the Hang Seng index?
- 3 Hot Stock Upgrades as Analysts Look Ahead to Q2 Earnings
- 3 Warren Buffett Stocks to Buy Now
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
